Fig. 9

SBZP remodels the immune microenvironment of residual tumors after IRFA. A, B The expression and quantitative analysis of CRT and HMGB1 in residual tumors treated with different NPs via CLSM (n = 3). C Levels of IFN-γ, TNF-α, IL-6, and TGF-β in IRFA mice serum treated with different NPs by ELISA (n = 4). D, E The maturation and quantitative analysis of DCs in tumor-draining lymph nodes in IRFA mice treated with different NPs via flow cytometry (n = 3). F, G Representative flow cytometry plots and quantitative assessments of CD4⁺ T cells, CD8⁺ T cells, CD11C⁺ DCs and CD11b⁺/F4/80⁺ TAMs (of CD45⁺ gate) in residual tumor treated with different NPs (n = 3). Results were expressed as mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001